Table 4.
Exosomes and Their Components as Therapeutic Targets for Endometrial Cancer.
| Biomarker | Trend | Type | Source | Recipient cells | Functions | Mechanisms | Application | Ref |
|---|---|---|---|---|---|---|---|---|
| miR-26a-5p | Decrease | miRNA | Plasma | Cancer cells/HLECs | Inhibit proliferation, migration, invasion, tumor growth, lymph node metastasis | LEF1 | Therapeutic target/nanocarrier | 88 |
| miR-21 | Increase | miRNA | Hypoxic cancer cells | Macrophages | Enhance M2 polarization | - | 89 | |
| miR-148b | Decrease | miRNA | CAFs | Cancer cells | Inhibit invasion, metastasis | DNMT1 | Therapeutic target/ nanocarrier | 90 |
| miR-320a | Decrease | miRNA | CAFs | Cancer cells | Inhibit proliferation, migration, invasion | HIF1α/VEGFA | Therapeutic target/ | 91 |
| miR-499a-5p | Decrease | miRNA | MSCs | Cancer cells/endothelial cells | Inhibit migration, invasion, tumor growth, angiogenesis | VAV3 | Therapeutic target/nanocarrier | 92 |
| miR-503-3p | - | miRNA | hUMSCs | Cancer cells | Migration, invasion, tumor growth | MEST | Therapeutic target/ nanocarrier | 93 |
| miR302a | - | miRNA | hUMSCs | Cancer cells | Proliferation, migration, invasion | Cyclin D1/AKT | Therapeutic target/nanocarrier | 94 |
| miR-192-5p | Decrease | miRNA | TAMs | Cancer cells | Enhance apoptosis, inhibit EMT | IRAK1/NF-κB | Therapeutic target/ nanocarrier | 95 |
| lncRNA DLEU1 | Increase | lncRNA | Cancer cells | Cancer cells | Enhance proliferation, migration, invasion, tumor growth | miR-381-3p/E2F3 | Therapeutic target | 96 |
| lncRNA NEAT1 | Increase | lncRNA | Cancer cells | Cancer cells | Enhance tumor growth | miR-26a/b-5p/STAT3/YKL-40 | Therapeutic target | 97 |
| circ_0001610 | Increase | circRNA | M2 macrophages | Cancer cells | Enhance radiosensitivity, tumor growth | miR-139-5p/cyclin B1 | Therapeutic target | 98 |
| miR-765 | Decrease | miRNA | CD45RO-CD8+ T cells | Cancer cells | Inhibit EMT, invasion, tumor growth, metastasis | ERβ//PLP2/Notch | Therapeutic target/nanocarrier | 99 |
| tRF-20-S998LO9D | Decrease | tsRNA | Cancer cells/serum | Cancer cells | Inhibit proliferation, migration, invasion, increase apoptosis | SESN2 | Therapeutic target | 100 |
HLECs: human lymphatic endothelial cells; EMT: epithelial–mesenchymal transition.